MetaVia Inc. — Director's Dealing 2020

Jan 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2019-12-30

Reporting Person: Versavel Mark (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-30	Stock Option (right to buy)	$0.63	A	297206	Acquired	2029-01-28	Common Stock (297206)	Direct
2019-12-30	Stock Option (right to buy)	$0.63	A	45724	Acquired	2029-01-31	Common Stock (45724)	Direct

Footnotes

F1: 70,000 shares underlying the option shall become vested shares upon certain milestones in relation to the Issuer's the Phase III US NB-01-301 study; 60,000 shares underlying the option shall become vested shares upon certain regulatory milestones related to the Issuer's product candidate,NB-02; an additional 70,000 option shares shall become vested shares upon the occurrence of certain additional milestones related to the Issuer's Phase III US NB-01-301; 15,000 shares underlying the option became vested shares on January 28, 2019; and an additional 7,500 of shares underlying the option became vested share on each of February 1, 2019, May 1, 2019, August 1, 2019, and November 1, 2019, with an additional 7,500 shares underlying the option to vest on each of February 1, 2020 and May 1, 2020.

F2: Reflects the Reporting Person's stock option to acquire 260,000 shares of private NeuroBo Pharmaceuticals, Inc. ("NeuroBo") common stock for $0.72 per share that was assumed by the Issuer in the Merger.

F3: 10,000 shares underlying the option became a vested share on the January 31, 2019, with an additional 5,000 shares vesting on each of February 1, 2019, May 1, 2019, August 1, 2019, November 1, 2019, February 1, 2020 and May 1, 2020.

F4: Reflects the Reporting Person's stock option to acquire 40,000 shares of NeuroBo common stock for $0.72 per share that was assumed by the Issuer in the Merger.